Omep (Omeprazole)

Omeprazole, the active ingredient in Omep, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the acid‑secretion pathway in the stomach. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prophylaxis: lowers risk of ulcer development in at‑risk patients.

Omeprazole is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: watery stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild cramping. - Flatulence: increased intestinal gas. - Constipation: infrequent, hard stools.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Liver enzyme elevation: increased ALT/AST levels indicating hepatic stress. - Fracture risk: potential reduction in bone mineral density with long‑term use.

When prescribing Omeprazole, clinicians should consider several safety aspects: - Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Monitor for infections: prolonged acid suppression may increase risk of gastrointestinal infections. - Review concomitant medications: potential for altered absorption of drugs that require an acidic environment. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: decreased absorption, compromising HIV therapy effectiveness. - Dasatinib: lowered plasma concentrations, reducing anticancer activity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Phenytoin: decreased serum levels, potentially reducing seizure control. - Methotrexate: elevated levels may occur, especially at high doses. - Digoxin: increased serum concentration, necessitating dose adjustment.